1-800-573-6274

Buprenorphine-Suboxone

Ibogaine Treatment for Suboxone

Buprenorphine was initially clinically investigated for use as a quick opioid taper designed to help pregnant women controllably withdraw off of opioids so that they would not give birth while physically dependent to opioids.

The suboxone formula consists of buprenorphine alongside a minor amount of naloxone and the drug is prescribed today for the treatment of sever pain as well as an ongoing replacement therapy for opioid dependency.

Suboxone acts as a long acting opioid analgesic predominantly interacting with the μ­-opioid receptor in the brain.

The buprenorphine in suboxone can best be described as an agonist / antagonist for its ability to bind aggressively to opioid receptor sites; acting as an agonist at mu-receptor while yielding an antagonist affect the at kappa-opioid receptor.

Buprenorphine, the prominent ingredient in suboxone, is highly liphilic and thus becomes saturated throughout adipose tissue in the body, especially compounding in areas surrounding the brain and central nervous system.

 

Once a Suboxone user reaches “steady’state” levels of buprenorphine in the plasma compounding of the agent begins and Suboxone basically saturates all of the of the fatty tissues of the body causing low levels of plasma concentrations of suboxone to reside for weeks for weeks in the body after a suboxone user has finished orally taking the drug.

 

For a patient planning on undergoing ibogaine treatment, suboxone use can be problematic for multiple months after discontinuing the oral use suboxone.   This is problematic due to the residual level of plasma concentrations of buprenorphine that’s remains in the adipose tissues of the suboxone user’s fatty tissue.

 

A former suboxone user who wishes to experience ibogaine and receive the full benefit from the medicine they must respect a 6 week minimum period off of suboxone. This is known as a drug -free time zone.

 

In this case the former suboxone user would not actually be expected to go ‘technically’ drug -free. He or she would be utilizing short-acting opioids and be free from the suboxone until the time for the ibogaine treatment arrives.

 

Once suboxone breaks down within the body the buprenorphine is further metabolized into norbuprenorphine.     Later on buprenorphine’s grandchildren metabolites come into play through the process of biotransformation which takes place in the liver.

Once ingested Suboxone’s chemistry translates from buprenorphine into the following generation of grandchildren metabolites that are known for running amuck in the lipid rich territories.

So for the record, Suboxone’s relentlessly stubborn grandchildren metabolites are…

 

norbuprenorphine

buprenorphine­3­glucuronide,

&

norbuprenorphine­3­glucuronide.

 

  • What people rarely speak about are the half lives of the culprits above…Most often people speak solely on the mother compound Buprenorphine, ignoring the respective residual potentials of the generational metabolites which have embedded themselves into adipose tissue suspended throughout a suboxone user’s body.

It should be understood that for ibogaine to function freely in the brain and body, its heroic desmethyl metabolite, nor-ibogaine must be allowed to enter lipid rich areas of the body, especially those opioid receptors responsible for neurotransmitter integrity in the brain and central nervous system.

Since suboxone became such a widely used compound, ibogaine providers have searched for a designated time frame to allow suboxone and its metabolic family to the leave the future ibogaine patient’s body free from buprenorphine spawned residue in order to be able to administer a proper ibogaine treatment without health repercussions along with the assurance of the many benefits of the ibogaine therapy.

The reality with suboxone is that 6 weeks is the minimum amount of time a former suboxone user should wait prior to undergoing ibogaine.

Ideally a former suboxone user would wait twice that long, making the three month point the goal in order to assure that no buprenorphine metabolites are left hanging around the fatty tissues that could lead to interference with ibogaine treatment.

 

Lex Kogan is an American author and medicinal veteran working directly with ibogaine since the year 2000.